Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing non-antibiotic, oral solutions for the prevention and control of gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.

     

News

Anatara Lifesciences Ltd (ASX:ANR) Annual Report to Shareholders

🕔10/14/2016 11:17:04 AM 2091

Anatara Lifesciences Ltd (ASX:ANR) directors present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the year ended 30 June 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives R&D Tax Refund

🕔10/14/2016 8:30:42 AM 1652

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara's 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/13/2016 8:25:28 AM 1622

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Read Full Article

Anatara Lifesciences Limited's (ASX:ANR) Antibiotic Alternative Edges Closer to Commercialisation as UN Declares Drug Resistance 'The Greatest and Most Urgent global risk'

🕔10/4/2016 8:30:00 AM 1864

Following the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), Anatara Lifesciences (ASX:ANR) confirmed its commitment to fighting AMR, starting with the food chain. Anatara, which is developing therapeutics for gastrointestinal diseases in production animals and humans announced today it had submitted an application to register Detach(TM).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) APVMA Submission Major Milestone Achieved

🕔10/4/2016 8:29:45 AM 2290

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has lodged its application for approval to register Detach(TM) with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach(TM) is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful Completion of Target Safety Study

🕔9/8/2016 8:27:28 AM 2520

Anatara Lifesciences (ASX:ANR) is pleased to announce the successful completion of its pivotal Target Animal Safety (TAS) Study for DetachTM, the Company's lead product for the control of diarrhoea in piglets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4E and Financial Report

🕔8/30/2016 8:20:29 AM 2022

Anatara Lifesciences Ltd (ASX:ANR) today released its Appendix 4E for the period ending 30th June 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4C - Quarterly

🕔7/22/2016 8:47:40 AM 1894

Chairman & CEO, Dr Mel Bridges said, "We are extremely pleased to report a positive cash flow for the last quarter, reinforcing a strong balance sheet and cash position. Our cash position allows Anatara the flexibility to execute on moving both our animal and human applications forward to commercial launch," Dr Bridges added.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation and Update

🕔7/11/2016 9:49:57 AM 2184

Anatara Lifesciences (ASX:ANR) releases its latest institutional roadshow presentation and market update. This week CEO & Chairman Dr Mel Bridges and Co-Founder and Chief Scientific Officer (CSO) Dr Tracey Mynott will be conducting a roadshow updating existing and potential new institutional investors and analysts.

Read Full Article

FINANCE VIDEO: Anatara Lifesciences Ltd (ASX:ANR) Executive Interview Series with Chief Scientific Officer Dr. Tracy Mynott

🕔6/30/2016 2:32:40 PM 8194

Anatara Lifesciences Limited (ASX:ANR) Chief Scientific Officer, Dr. Tracy Mynott, speaks with Tom Piotrowski at CommSec's The Executive Series, by Commonwealth Bank Australia (ASX:CBA).

Read Full Article
###

7,251 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 82) (Last 30 Days: 422) (Since Published: 7251) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Social Media